WO1999045116A3 - Human homolog of a nuclear migration gene and its use - Google Patents
Human homolog of a nuclear migration gene and its use Download PDFInfo
- Publication number
- WO1999045116A3 WO1999045116A3 PCT/US1999/004996 US9904996W WO9945116A3 WO 1999045116 A3 WO1999045116 A3 WO 1999045116A3 US 9904996 W US9904996 W US 9904996W WO 9945116 A3 WO9945116 A3 WO 9945116A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gene
- human homolog
- nuclear migration
- cell growth
- migration gene
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6875—Nucleoproteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU30713/99A AU3071399A (en) | 1998-03-05 | 1999-03-05 | Human homolog of a nuclear migration and its use |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7688598P | 1998-03-05 | 1998-03-05 | |
US60/076,885 | 1998-03-05 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO1999045116A2 WO1999045116A2 (en) | 1999-09-10 |
WO1999045116A3 true WO1999045116A3 (en) | 2000-02-10 |
WO1999045116A9 WO1999045116A9 (en) | 2000-07-27 |
Family
ID=22134770
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/004996 WO1999045116A2 (en) | 1998-03-05 | 1999-03-05 | Human homolog of a nuclear migration gene and its use |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU3071399A (en) |
WO (1) | WO1999045116A2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1774043A4 (en) * | 2004-05-28 | 2009-09-02 | Dana Farber Cancer Inst Inc | Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer |
CN100432102C (en) * | 2004-09-30 | 2008-11-12 | 百瑞全球有限公司 | Blood platelet reinforcing protein and application thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998033911A1 (en) * | 1997-01-31 | 1998-08-06 | Incyte Pharmaceuticals, Inc. | Human signal transduction protein regulating the nuclear movement |
-
1999
- 1999-03-05 WO PCT/US1999/004996 patent/WO1999045116A2/en active Application Filing
- 1999-03-05 AU AU30713/99A patent/AU3071399A/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998033911A1 (en) * | 1997-01-31 | 1998-08-06 | Incyte Pharmaceuticals, Inc. | Human signal transduction protein regulating the nuclear movement |
Non-Patent Citations (6)
Title |
---|
CHIU Y.-H. ET AL.: "Extragenic Suppressors of nudC3, a Mutation That Blocks Nuclear Migration in Aspergillus nidulans", GENETICS, vol. 141, no. 2, October 1995 (1995-10-01), pages 453 - 464, XP002122521 * |
GOCKE C.D.: "EXPRESSION AND LOCATION OF HNUDC, A CELL GROWTH-RELATED PROTEIN, IN HUMAN TISSUE", LABORATORY INVESTIGATION, vol. 79, no. 1, January 1999 (1999-01-01), pages 175A, XP002122519 * |
HILLIER L. ET AL.: "The WashU-Merck EST Project; 592753 3' similar to TR:G619907 G619907 C15 MRNA", EMBL DATABASE ENTRY HSAA60698; ACCESSION NUMBER AA160698, 19 January 1997 (1997-01-19), XP002124443 * |
MILLER B.A. ET AL.: "A homolog of the fungal nuclear migration gene nudC is involved in normal and malignant human hematopoiesis", EXPERIMENTAL HEMATOLOGY, vol. 27, no. 4, April 1999 (1999-04-01), pages 742 - 750, XP002122520 * |
MORRIS N. R. ET AL.: "Nuclear migration, nucleokinesis and lissencephaly", TRENDS IN CELL BIOLOGY, vol. 8, December 1998 (1998-12-01), pages 467 - 470, XP002122522 * |
MORRIS S.M. ET AL.: "Expression of RNUDC, a Potential Nuclear Movement Protein, in Mammalian Cells: Localization to the Golgi Apparatus", EXPERIMENTAL CELL RESEARCH, vol. 238, no. 1, January 1998 (1998-01-01), pages 23 - 32, XP002122518 * |
Also Published As
Publication number | Publication date |
---|---|
WO1999045116A9 (en) | 2000-07-27 |
AU3071399A (en) | 1999-09-20 |
WO1999045116A2 (en) | 1999-09-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IE870201L (en) | "a method for the expression of genes in plants, parts of¹plants, and plant cell cultures, and dna fragments,¹plasmids, and transformed microorganisms to be used when¹carrying out the method, as well as the use thereof for the¹expression of genes in plants parts of plants, and plant¹cell cultures" | |
AP2000001762A0 (en) | Method of delivering genes to antigen presenting cells of the skin | |
CA2149329A1 (en) | Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma | |
TW376320B (en) | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma | |
EP0400958A3 (en) | Live vaccines | |
AU6649996A (en) | Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease | |
HU883981D0 (en) | Process for the production of medical preparations with antiviral or antibacterial effect | |
MX9801264A (en) | Control of cd44 gene expression for therapeutic use. | |
JPS6463505A (en) | Cosmetics | |
WO1999015643A3 (en) | ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS TARGETED TO ANGIOTENSI N CONVERTING ENZYME mRNA AND METHODS OF USE | |
EP1189918A4 (en) | Antisense modulation of integrin beta 3 expression | |
WO2002064088A3 (en) | Pharmaceutical composition for the treatment of alopecia | |
HUP9900654A3 (en) | Preparations stimulating nail growth, process for their preparation and use of them | |
CA2083377A1 (en) | Compositions and methods for modulating rna activity through modification of the 5' cap structure of rna | |
EP0209543A4 (en) | Peptide fragments of human apolipoprotein, type-specific antibodies and methods of use. | |
AU1502695A (en) | Double stranded RNA correction of abherrant metabolic pathways associated with uncontrolled tumor cell and virus growth cycles | |
BR9811014A (en) | "concentrated gene regulatory region specifically for early seed" | |
WO1999045116A3 (en) | Human homolog of a nuclear migration gene and its use | |
WO2003000222A3 (en) | Cosmetic preparation with anti-wrinkle action | |
WO2000079267A3 (en) | Use of hte ubiquitin specific protease usp25 in the treatment, prophylaxis and diagnosis of cancer | |
SG74579A1 (en) | Enzyme with leudh activity, nucleotide sequence coding therefor and process for the preparation of the enzyme | |
AU6125496A (en) | Human growth factors, nucleotide sequence encoding growth factors, and methods of use thereof | |
MD1119G2 (en) | Method for female genitals inflammatory diseases treatment | |
WO2001042448A3 (en) | Artificial promoters for protein expression in plants | |
Näthke et al. | Glucosylated plasma protein injection does not produce glomerular basement membrane thickening |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AU CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AU CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: C2 Designated state(s): AU CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: C2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
COP | Corrected version of pamphlet |
Free format text: PAGES 1/12-12/12, DRAWINGS, REPLACED BY NEW PAGES 1/12-12/12; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09623568 Country of ref document: US |
|
122 | Ep: pct application non-entry in european phase |